Asthma Pharmacotherapy: Stepwise Approach to Managing Asthma

Karen Meyerson, MSN, APRN, NP-C, AE-C
Asthma Network of West Michigan
June 2015
Asthma Pharmacotherapy

**Quick-relief**
- Short-acting beta-agonists
- Inhaled anticholinergics
- Systemic corticosteroids

**Long-term control**
- Corticosteroids
- Cromolyn sodium
  - Mast cell stabilizer
  - Only available in nebulized form
- Long-acting inhaled beta-agonists
- Theophylline
- Leukotriene Receptor Antagonists (LTRA)
Quick-Relief Medications

- Short-acting beta$_2$-agonists (SABA): albuterol (Pro-Air, Ventolin, Proventil); levalbuterol (Xopenex)
- Relax bronchial smooth muscles
- Short-acting
  - Work within 10 - 15 minutes
  - Last 4 - 6 hours
- Bind to and activate beta$_2$ receptors in cardiac and smooth muscle tissues
  - Cause bronchodilation in lungs
  - Side effects can include shakiness (tremors), tachycardia
- (Older) beta-blockers are contraindicated in asthma as they can cause the opposite effect - bronchoconstriction
- Danger of over-use
Short-acting $\beta_2$-agonists (SABA)

- Most effective medication for relief of acute symptoms

**RED FLAG**
- more than 2 canisters per year

- Regularly scheduled use not generally recommended
  - May “lower” effectiveness
  - May increase airway hyperresponsiveness
Anticholinergics

- Ipratropium bromide (Atrovent) or ipratropium bromide & albuterol (Combivent)
- Not specifically indicated for “usual” quick-relief medication in asthma
  - contrast with COPD
- Now well-studied as adjunct to beta-agonists in emergency departments
  - i.e., acute exacerbations
Long-term Control Medications

- **Inhaled corticosteroids (ICS):** fluticasone (Flovent); beclomethasone (QVAR); budesonide (Pulmicort); mometasone (Asmanex); ciclesonide (Alvesco); triamcinolone (Aerospan)

- **Combination products (inhaled corticosteroids and long-acting beta\(_2\)-agonists or ICS/LABA):**
  - fluticasone & serevent (Advair)
  - budesonide & formoterol (Symbicort)
  - mometasone & formoterol (Dulera)

- **Leukotriene receptor antagonist (LTRA):** montelukast (Singulair), zafirlukast (Accolate), zileuton (Zyflo)

- **Methylxanthines:** theophylline (Theo-Dur, Slo-bid)

- **Anti-IgE blocker:** omalizumab (Xolair)
Long-term Control Medications

- Should be taken daily and chronically to maintain control of persistent asthma and to prevent exacerbations:
  - Soothes airway swelling
  - Helps prevent asthma flares - very effective for long-term control but must be taken daily
  - Often under-used
Inhaled Corticosteroids (ICS)

- Actions:
  - potentiate $\beta$-receptor responsiveness
  - reduce mucus production and hypersecretion
  - inhibit inflammatory response at all levels
- Best effects if started early after diagnosis
- Symptomatic and spirometric improvement within 2 weeks
  - maximum effects within 4-8 weeks
Inhaled Corticosteroids (ICS) (continued)

- **THE** most effective long-term control medication for persistent asthma
- Small risk for adverse events at usual doses
  - Risk can be reduced even further by:
    - Using spacer and rinsing mouth
    - Using lowest effective dose
    - Using with long-acting $\beta_2$-agonist when appropriate
    - Monitoring growth in children
Low dose ICS and the Prevention of Asthma Deaths

- ICS protects patients from asthma-related deaths
- Users of > 6 canisters/yr. had a death rate ~ 50% lower than non-users of ICS
- Death rate decreased by 21% for each additional ICS canister used during the previous year.

ICS May Help Prevent the Risk of Asthma Related Hospitalizations

Short-acting $\beta_2$ prescriptions dispensed per person-year

Adapted from Donahue et. al. JAMA 1997;277(11):887-891.
Inhaled Corticosteroids (ICS) (continued)

- Hypothalamic-pituitary-adrenal (HPA) suppression
  - Not seen in usual doses

- Cataracts
  - Not seen in usual doses

- Long bone growth
  - Growing understanding of this risk
  - Childhood Asthma Management Program (CAMP) study (2000)* showed small, transient reduction in growth velocity from ICS
  - Update (2012)** showed growth reduction persisted as lowered adult height (1.2 cm) – need to weigh risks & benefits

- Osteoporosis/Bone Fractures
  - Some attention at high doses, high-risk patients

- Candidiasis (thrush)

- Dysphonia (hoarseness)

---

Leukotriene Receptor Antagonists (LTRA)

- Two mechanisms
  - 5-lipoxygenase inhibitors
    - zileuton (Zyflo)
  - Cysteinyl leukotriene receptor antagonists
    - zafirlukast (Accolate), montelukast (Singulair)

- Indications
  - Generally, alternative therapy in mild persistent asthma or as add-on in higher stages
    - Improve lung function
    - Decrease short-acting $\beta_2$-agonist use
    - Prevent exacerbations
Methylxanthines (Theophylline) (continued)

- Places in therapy:
  - When inhaled corticosteroids not possible
  - Patients who can’t/won’t use inhalers
  - Additive therapy at later stages

- Adverse Drug Reactions/Serum Levels
  - Therapeutic Range 5-15 mcg/mL, or 10-20 mcg/mL
  - Levels > 20 mcg/mL: nausea, vomiting, diarrhea, headache, irritability, insomnia, tachycardia
  - Levels > 30 mcg/mL: seizures, toxic encephalopathy, hyperthermia, brain damage

- Drug Interactions: PLENTY!!
Long-Acting $\beta_2$-Agonists

- Not a substitute for anti-inflammatory therapy
- Not appropriate for monotherapy

**RED FLAG**

- Literature supporting role in addition to inhaled corticosteroids
- Not for acute symptoms or exacerbations
- Salmeterol (Serevent) first of class in US
- Formoterol (Foradil)
  - Newer long-acting beta-agonist
  - Has rapid onset and long duration
  - Available as dry powder inhaler and in combination with inhaled steroid (Symbicort & Dulera)
Long-Acting $\beta_2$-Agonists

- Salmeterol Multicenter Asthma Research Trial (SMART)
- A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
The Salmeterol Multicenter Asthma Research Trial*

A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol

Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; and Paul M. Dorinsky, MD; and the SMART Study Group
Patients > 12 years old with asthma

Sought to evaluate the effects of salmeterol or placebo added to usual asthma care on

- respiratory and asthma related deaths
- life-threatening episodes

Initial aim to enroll 30,000 patients; later changed with aim to enroll 60,000
Long-Acting $\beta_2$-Agonists (LABAs)

- Increase in adverse events in salmeterol group during SMART trial:
  - Particularly in those recruited in Phase 1
  - Particularly among African-Americans who were noted to have markers of more severe asthma and less likely to be using ICS

- Increase in adverse events in salmeterol group:
  - Due to adverse effect of salmeterol?
  - Due to inappropriate bronchodilator use? (affected patients were more severe at baseline and less likely to be using ICS)
FDA Safety Requirements for Long-Acting $\beta_2$-Agonists (LABAs) in Asthma

- The use of LABAs is contraindicated without the use of an asthma controller medication such as an inhaled corticosteroid. Single-ingredient LABAs should only be used in combination with an asthma controller medication; they should not be used alone.

- LABAs should only be used long-term in patients whose asthma cannot be adequately controlled on asthma controller medications.

- LABAs should be used for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved. Patients should then be maintained on an asthma controller medication.

- Pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid should use a combination product containing both an inhaled corticosteroid and a LABA, to ensure compliance with both medications.

~ February 2010
Long-Acting $\beta_2$-Agonists (LABAs)

- Conclusions:
  - Black Box warning
  - Do not use long-acting bronchodilators alone
  - Always use with inhaled corticosteroids
  - Newer Data:
    - LABAs when used with inhaled corticosteroids are helpful. Multiple reviews/meta-analyses suggest that long-acting beta-agonists + inhaled corticosteroids reduce asthma hospitalizations compared to inhaled corticosteroids alone.
    - Emphasize the weakness of the primary data in terms of statistical strength, simply because asthma-related deaths and intubations are so rare.

Patients Are Candidates for Maintenance Therapy if the “RULES OF TWO”™* Apply…

- They are using a quick-relief inhaler more than 2 times per week
- They awaken at night due to asthma more than 2 times per month
- They refill a quick-relief inhaler Rx more than 2 times per year

*“RULES OF TWO”™ is a trademark of the Baylor Health Care System.
Out of Control!

Rules of Two™

- If your patient can answer “YES” to ANY of these questions, his/her asthma is probably not under good control.
- These rules define persistent asthma.
Asthma Severity

- Intermittent
- Mild Persistent
- Moderate Persistent
- Severe Persistent
<table>
<thead>
<tr>
<th>Impairment</th>
<th>Classification of Asthma Severity</th>
<th>Persistent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intermittent</td>
<td>Mild</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe</td>
</tr>
<tr>
<td>Impairment</td>
<td>Symptoms</td>
<td>&lt;2 days/week</td>
</tr>
<tr>
<td></td>
<td>Nighttime Awakenings</td>
<td>&lt;2x/month</td>
</tr>
<tr>
<td>Normal FEV₁/FVC</td>
<td>SABA use for sx control</td>
<td>&lt;2 days/week</td>
</tr>
<tr>
<td>8-19 yr 85%</td>
<td>Interference with normal activity</td>
<td>none</td>
</tr>
<tr>
<td>20-39 yr 80%</td>
<td>Lung Function</td>
<td>Normal FEV₁ between exacerbations</td>
</tr>
<tr>
<td>40-59 yr 75%</td>
<td></td>
<td>• FEV₁ &gt; 80%</td>
</tr>
<tr>
<td>60-80 yr 70%</td>
<td></td>
<td>• FEV₁/FVC normal</td>
</tr>
<tr>
<td>Risk</td>
<td>Exacerbations</td>
<td>0-2/year</td>
</tr>
<tr>
<td>(consider frequency and severity)</td>
<td></td>
<td>&gt; 2 /year</td>
</tr>
</tbody>
</table>

Risk Frequency and severity may vary over time for patients in any category

Relative annual risk of exacerbations may be related to FEV

Recommended Step for Initiating Treatment

<table>
<thead>
<tr>
<th>Step 1</th>
<th>Step 2</th>
<th>Step 3</th>
<th>Step 4 or 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>In 2-6 weeks, evaluate asthma control that is achieved and adjust therapy accordingly</td>
<td></td>
<td></td>
<td>Consider short course of oral steroids</td>
</tr>
</tbody>
</table>

EPR-3, p74, 344
Stepwise Approach for Managing Asthma in Youths > 12 Years and Adults

- **Persistent Asthma: Daily Medication**
  - Consult with asthma specialist if step 4 or higher care is required
  - Consider consultation at step 3

### Step 1
- **Preferred:** SABA prn
- **Alternative:** Low-dose ICS, LTRA, Cromolyn, Theophylline, Or Zileutin

### Step 2
- **Preferred:** Medium-dose ICS
- **Alternative:** Low-dose ICS + LABA, LTRA, Theophylline, Or Zileutin

### Step 3
- **Preferred:** Medium-dose ICS + LABA
- **Alternative:** Low-dose ICS + either LABA, LTRA, Theophylline, Or Zileutin

### Step 4
- **Preferred:** Medium-dose ICS + LABA
- **Alternative:** Low-dose ICS + either LABA, LTRA, Theophylline, Or Zileutin

### Step 5
- **Preferred:** High dose ICS + LABA
- **And:** Consider Omalizumab for patients with allergies

### Step 6
- **Preferred:** High-dose ICS + LABA + oral Corticosteroid
- **And:** Consider Omalizumab for patients with allergies

**Assess Control**
- Step up if needed (check adherence, environmental control and comorbidities)
- Step down if possible (asthma well controlled for 3 months)

**Patient Education and Environmental Control at Each Step**

**EPR-3, p333-343**
Asthma Control

The purpose of periodic assessment and ongoing monitoring is to determine whether the goals of asthma therapy are being achieved and asthma is controlled.

- **Well Controlled**
- **Not Well Controlled**
- **Very Poorly Controlled**
### Classification of Asthma Control

<table>
<thead>
<tr>
<th></th>
<th>Well Controlled</th>
<th>Not Well Controlled</th>
<th>Very Poorly Controlled</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IMPAIRMENT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td>≤ 2 days/week</td>
<td>&gt; 2 days/week</td>
<td>Throughout the day</td>
</tr>
<tr>
<td>Nighttime awakenings</td>
<td>&lt; 2/month</td>
<td>1-3/week</td>
<td>&gt; 4/week</td>
</tr>
<tr>
<td>Interference with normal activity</td>
<td>none</td>
<td>Some limitation</td>
<td>Extremely limited</td>
</tr>
<tr>
<td>SABA use</td>
<td>≤ 2 days/week</td>
<td>&gt; 2 days/week</td>
<td>Several times/day</td>
</tr>
<tr>
<td>FEV1 or peak flow</td>
<td>&gt; 80% predicted/ personal best</td>
<td>60-80% predicted/ personal best</td>
<td>&lt;60% predicted/ personal best</td>
</tr>
<tr>
<td>Validated questionnaires</td>
<td>0/&gt; 20</td>
<td>1-2/16-19</td>
<td>3-4/&lt; 15</td>
</tr>
<tr>
<td>ATAQ/ACT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exacerbations</td>
<td>0- 1 per year</td>
<td>2 - 3 per year</td>
<td>&gt; 3 per year</td>
</tr>
<tr>
<td>Progressive loss of lung function</td>
<td>Evaluation requires long-term follow up care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rx-related adverse effects</td>
<td>Consider in overall assessment of risk</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Recommended Action for Treatment

- **Maintain current step**
- **Step up 1 step**
- **Consider oral steroids**
- **Step up (1-2 steps) and reevaluate in 2 weeks**

- **Consider step down if well controlled at least 3 months**
- **Reevaluate in 2 - 6 weeks**
Current Therapy

- Use Asthma Guidelines as a guide
- Poor adherence with inhaled therapy
- No curative therapy
- Many patients remain poorly controlled
- Recognition of different phenotypes of asthma
New/Upcoming Asthma Therapies

- Recognition that there are different phenotypes or endotypes of asthma
  - Phenotype – observable characteristics or clinical presentation (e.g., transient vs. persistent wheezing)
  - Endotype – a subtype of a condition defined by a distinct pathophysiological mechanism

- As treatments become more specific, targeting specific inflammatory cells (such as blockade of specific cytokines or kinases) may be effective in the treatment of asthma

- Because new therapies are likely to be very expensive (especially antibodies) it will become increasingly important to recognize responder patients
New Bronchodilators

- Prevention and relief of bronchoconstriction
- LABAs offered 12 hour action
  - Salmeterol (Serevent), formoterol (Foradil)
- Now Ultra-LABAs in development with 24-hour action
  - Indacaterol, carmoterol, vilanterol and olodaterol.
Risks of LABAs

- Increased risk of overall death if monotherapy
- Evidence supports LABA + ICS in a single inhaler device for patient with mod/severe asthma

Thorax 2012; 67: 67 342-349
ProAir RespiClick
albuterol sulfate dry powder inhaler

• For ages > 12
• Breath actuated
Side Effects

- Back pain
- Body aches and pains
- Upset stomach
- Heart racing
- Urinary tract infection
- Shakiness
Once daily maintenance therapy of asthma in those 12 and older

Normal dose is one inhalation daily

Starting dose is 100mcg

May increase to 200mcg after 2 weeks
Side Effects

- Upper infections
- Nasopharyngitis
- Headache
- Bronchitis
- Oral candidiasis
LABA/Corticosteroid

- New products aimed for ease of use and adherence to therapy
- One inhalation/once daily
Breo Ellipta
fluticasone furoate/vilanterol

- FDA approval 4/30/2015 for ages 18 and older
- LABA warning continues
- Once daily inhalation therapy for individuals with asthma
- Side Effects - Headache, nasopharyngitis, pneumonia, fractures
New Inhalation Device

Respimat

- Combivent
  - albuterol and ipratropium
- Spiriva
  - tiotropium
Omalizumab (Xolair)  
Anti-IgE Therapy

- Biologic antibody therapy binds IgE in the circulation and prevents it from activating mast cells and basophils.
- In moderate to severe asthma, anti-IgE therapy reduced exacerbation rate and reduced steroid dose needed.
- Anti IgE therapy is recommended as an add-on to optimized standard therapy in individuals 12 years and older who need continuous or frequent treatment with oral corticosteroids.
- Elevated serum IgE 30-700 IU/ml
- Positive allergy test
Omalizumab (Xolair) is indicated for adults and adolescents 12 years of age and above:

- With moderate to severe, persistent asthma
- Who have a positive skin test or *in vitro* reactivity to a perennial aeroallergen
- Whose symptoms are inadequately controlled with inhaled corticosteroids
- Elevated serum immunoglobulin E (IgE) level (≥ 30-700 IU/mL)

Xolair has been shown to decrease the incidence of asthma exacerbations in these patients.

Safety and efficacy have not been established in other allergic conditions.
Bronchial Thermoplasty

- Indicated for treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and LABAs
- Performed with a bronchoscope – involves the delivery of controlled, therapeutic radiofrequency energy to the airway wall
- This results in heating of the tissue and reduces the amount of smooth muscle present in the airway way
- Requires 3 separate bronchoscopic procedures
- Reduces asthma exacerbations, ER visits and hospitalizations
Timothy Grass Extract
Grastek

- Used for grass pollen-induced allergic rhinitis confirmed by positive allergy testing
- Dose one tablet sublingual daily
- First dose in allergy office (observed for 30 minutes), then taken once daily at home
- Leave under tongue for at least 1 minute.
- Start 12 weeks before grass season
- Ages 5-65
- Do not use in severe or uncontrolled asthma.
Timothy Grass Extract

- **Side effects**
  - Throat irritation
  - Itchy ears
  - Oral itching
  - Mouth edema
  - Headache

- **Stop taking if** trouble breathing, throat tightness or swelling, trouble swallowing, dizziness, rapid heartrate, severe stomach symptoms

- **Possibility of systemic (anaphylactic) reaction** (lower risk than immunotherapy injections)

- Should have an EpiPen prescribed for home use
Grass Pollen Extract
Oralair

- Used for treatment of grass pollen-induced allergic rhinitis confirmed by positive allergy testing
- 5 grass species included
- Dose: one sublingual tab daily
- Ages 10-65
- Do not use in uncontrolled asthma
Grass Pollen Extract

- **Side Effects**
  - Oral itching
  - Throat irritation
  - Ear itching
  - Edema mouth

- Stop taking if trouble breathing, throat tightness or swelling, trouble swallowing, dizziness, rapid heart rate, severe stomach symptoms

- Possibility of systemic (anaphylactic) reaction (lower risk than immunotherapy injections)

- Should have an EpiPen prescribed for home use
Short Ragweed Pollen Extract
Ragwitek

- Indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis confirmed by positive allergy testing
- Dose one tablet sublingual daily
- Start 12 weeks prior to season
- Ages 18-65
- Do not use in severe or uncontrolled asthma
Short Ragweed Pollen Extract

- **Side Effects**
  - Throat irritation
  - Ear itching
  - Oral itching
  - Mouth tingling
  - Mouth edema

- Stop taking if throat tightness or swelling, trouble breathing, trouble swallowing, dizziness, rapid heart rate, severe stomach problems

- Possibility of systemic (anaphylactic) reaction (lower risk than immunotherapy injections)

- Should have an EpiPen prescribed for home use
What is Success: How do we measure it and how do we get there?

- Begin therapy based on **Severity**
- Monitor and adjust therapy based on **Control** and **Risk** and **Responsiveness to Therapy**
- Use routine standardized multifaceted measures
- The goal of therapy is to achieve control
- Individualize therapy based on likelihood of response and patient needs, desires and goals
Questions?

- Karen Meyerson, MSN, APRN, NP-C, AE-C

  - Phone: 616-685-1432
  - E-mail: meyersok@mercyhealth.com
